Question Bank › Event-dense runway

Event-dense runway

Event-dense runway: management frames the coming quarters as a calendar of its own named, scheduled events

Calls Tested
422
Answered YES
22
Hit Rate
5.2%
rare by design

Toast, Inc. (TOST) — this company's answers

NO on the Q4 2022 call 2023-02-16 C+
The model's full reasoning — Q4 2022 call → NO我们根据指令,只使用提供的财报电话会议记录。问题:管理层是否将公司近期未来(大约未来几个季度)描述为一系列具体的、已命名的、已安排的公司自身事件的日历,并将完成这一事件序列作为公司未来走向的核心叙事? 分析记录内容: - 管理层提到了“Delphi Display Systems”的收购,以提供得来速能力。这是一个具体的、已命名的、即将发生的事件(收购已宣布,整合正在进行)。 - 管理层提到了“Order with Google”集成,作为扩展数字订购产品套件的一部分。这也是一个具体的、已命名的、已宣布的集成。 - 管理层提到了“Toast invoicing”的推出(在Q3推出,已有超过5000客户使用),但这是过去的事件。 - 管理层提到了“Toast for quick-serve restaurants”在Q2推出,并提到“我们计划在2023年继续增加更多QSR能力”,但这是模糊的。 - 管理层提到了“国际业务”的扩张,但说“我们仍处于早期阶段”,没有具体时间表。 - 管理层提到了“2023年令人兴奋的产品管线”,但没有具体命名或时间锚定。 - 管理层提到了“Q1季节性较低”等,但这是常规季节性。 关键点:管理层是否将未来几个季度组织为多个具体、已命名、已安排的公司事件?有收购Delphi和Google集成,但这两个是已宣布的,且Google集成是“上周宣布的”,Delphi是“今天宣布的”。它们属于近期事件,但管理层是否将它们作为未来几个季度的核心叙事?管理层在讨论未来时,更多是谈论宏观环境、需求韧性、成本纪律、利润率改善等。他们提到了“2023年产品管线”,但没有具体命名或时间。他们提到了“国际扩张”但说“多年度旅程”。他们提到了“QSR能力”但说“计划增加”。 指令要求:有多个不同的具体事件,管理层在近期时间锚定它们,并将这一事件序列作为公司下一阶段的主要引擎。这里只有两个具体事件(Delphi和Google),且它们都是已宣布的,不是未来几个季度的日历。管理层没有说“本季度我们将推出X,下季度我们将推出Y”等。他们更多是谈论持续增长、利润率改善、宏观不确定性。因此,答案应为NO。 最终答案:NO。

← Back to the full TOST analysis

Show the exact prompt the model was given
Using ONLY the supplied earnings call transcript and no outside information: On this call, does management frame the company's NEAR FUTURE — roughly the next few quarters — as a CALENDAR OF ITS OWN SPECIFIC, NAMED, ALREADY-SCHEDULED EVENTS, and treat working through that event sequence as the central story of where the company is heading? Answer YES when management's own words convey, in whatever form fits the business, ONE coherent posture: the forward-looking discussion is organized around MULTIPLE distinct, concrete happenings that belong to the company itself and are expected to occur soon — each one identifiable and time-anchored in management's telling (this quarter, next quarter, by mid-year, this season, in the coming months). The events may take whatever form fits the industry — for example: a facility, line, site, store format, or capacity starting up or opening; a product, program, service, or offering launching or shipping; a ramp, rollout, or expansion beginning or reaching its next stage; a first delivery, first production, first cohort, or go-live; a submission, decision, certification, data readout, or approval date; a contract, program, or partnership commencing; a new market or channel switching on. What matters is that (a) there are SEVERAL such distinct company-specific events, not just one; (b) management anchors them in the near term with at least rough timing, presenting them as scheduled or in motion rather than aspirational; and (c) management treats this sequence of upcoming events — rather than general market conditions, demand trends, or cost management — as the main engine of the company's next stage, with the call's forward energy devoted to what is about to happen and how the company is preparing for each step. Answer NO if the forward discussion is chiefly about market conditions, demand strength or weakness, macro factors, pricing, or cost control, with no calendar of company-specific events. NO if there is only ONE meaningful upcoming event, however large. NO if the future items are vague ambitions, pipeline hopes, exploratory initiatives, or opportunities without stated near-term timing. NO if the named events are routine recurring housekeeping this business always has (ordinary seasonal openings at the usual pace, standard annual product refreshes, scheduled maintenance) that management does not present as changing the company's trajectory. NO if management mentions upcoming milestones only in passing while the call's substance is defending current results. NO if the events are mainly things happening TO the company from outside (market recoveries, customer budget cycles, industry conditions) rather than the company's own scheduled actions. NO if the event calendar appears only in an analyst's question or summary that management does not itself adopt. Use only the supplied transcript. Answer only YES or NO.

Companies that answered YES

TickerCompanyCallDateCall grade
RCEL AVITA Medical, Inc. Q1 2024 2024-05-14 F
ERO Ero Copper Corp. Q1 2024 2024-05-10 A
LILA Liberty Latin America Ltd. Q4 2023 2024-02-23 C
BRBR BellRing Brands, Inc. Q4 2023 2023-11-21 B+
SBS Companhia de Saneamento Básico do Estado Q3 2023 2023-11-10 C+
PTN Palatin Technologies, Inc. Q4 2023 2023-09-29 D
NBTX Nanobiotix S.A. Q2 2023 2023-09-27 D
PTLO Portillo's Inc. Q2 2023 2023-08-05 B
BEAT BioTelemetry's Q4 2022 2023-03-17 D
ARWR Arrowhead Pharmaceuticals, Inc. Q4 2022 2022-11-28 D
FLL Full House Resorts, Inc. Q3 2022 2022-11-07 B
ASTS AST SpaceMobile, Inc. Q2 2022 2022-08-15 D
HROW Harrow Health, Inc. Q4 2021 2022-03-10 C
EEX Emerald Holding, Inc. Q2 2021 2021-08-01 C+
AGIO Agios Pharmaceuticals, Inc. Q3 2018 2018-11-01 C
ALKS Alkermes plc Q3 2018 2018-10-23 C
AU AngloGold Ashanti's Q2 2018 2018-08-20 B
ITCI Intra-Cellular Therapies, Inc. Q4 2017 2018-03-01 D
PCRX Pacira BioSciences, Inc. Q4 2017 2018-02-28 C
IONS Ionis Pharmaceuticals, Inc. Q1 2017 2017-05-09 C
FATE Fate Therapeutics, Inc. Q3 2016 2016-11-07 C
DUK Duke Energy Corporation Q2 2016 2016-08-04 B

How the model reasoned

PCRX · Q4 2017 → YESThe question is: Does management frame the company's NEAR FUTURE — roughly the next few quarters — as a CALENDAR OF ITS OWN SPECIFIC, NAMED, ALREADY-SCHEDULED EVENTS, and treat working through that ev...YES Management frames the near-term outlook (2018) as a concrete calendar of its own named, time-anchored events—nerve-block label expansion, C-section study readout, additional Phase 4 study launches, CMS reimbursement decisions, and new partnerships—treating the execution of this sequence as the primary driver of 2018 growth and strategic progress. These are presented as scheduled company actions rather than general market trends, with explicit timing (e.g., mid-year FDA meetings, second-half manufacturing ramp, AAOS programs) and positioned as the central story of where the company is heading.
AU · Q2 2018 → YESThe question is: Does management frame the company's NEAR FUTURE — roughly the next few quarters — as a CALENDAR OF ITS OWN SPECIFIC, NAMED, ALREADY-SCHEDULED EVENTS, and treat working through that ev...YES Management structures the forward outlook around a clear sequence of its own named, time-anchored events—Kibali underground ramp-up and Azambi hydropower station (Q3), Siguiri CIL circuit and power plants (Q4), Obuasi redevelopment milestones (first gold end-2019), Mponeng 6-month backfill plant start (H2), South Africa Section 189 process and wage negotiations (Q3), plus production upticks at multiple sites—presenting these as the primary drivers of the next stage rather than generic market or cost themes.
HROW · Q4 2021 → YESThe question is: Does management frame the company's NEAR FUTURE — roughly the next few quarters — as a CALENDAR OF ITS OWN SPECIFIC, NAMED, ALREADY-SCHEDULED EVENTS, and treat working through that ev...YES The transcript shows management organizing the near-term outlook around a clear sequence of its own named, time-anchored events: AMP-100 PDUFA on October 16 (with launch a few months later), Surface Opthalmics data readout in a few months, Melt Pharmaceuticals top-line data soon after, and internal product 18-month launches, plus MAQ-100 FDA meeting mid-year and relaunch preparations for IOPIDINE/MAXITROL/MOXEZA.

More from the question bank

Second engine igniting off the firstManagement is buying/committing capital at aThe leak is fixed: the company is keeping whDemand pull is outrunning the plan for one sBet-the-company financing already spent on hSaid-then-did: management reports back on itAll questions →
Not investment advice. Artul.ai publishes AI-generated earnings-call quality grades and expected-volatility estimates — never buy or sell recommendations. We tested over 1,600 predictive hypotheses against 165,000 transcripts; the honest result, including what failed, is documented in our methodology.